In short
Bemarituzumab is an investigational drug being studied in clinical trials for the treatment of various types of cancer, particularly advanced gastric and gastroesophageal junction cancers. This article explores the ongoing research on bemarituzumab, its potential benefits, and its role in combination with other cancer therapies.
At a glance
- Drug Name
- Bemarituzumab (also known as AMG 552)
- Primary Cancer Types Studied
- Advanced gastric cancer, gastroesophageal junction cancer
- Other Cancer Types
- Solid tumors with FGFR2b overexpression, squamous-cell non-small-cell lung cancer
- Administration Method
- Intravenous (IV) infusion
- Treatment Approaches
- Monotherapy, combination with chemotherapy, combination with immunotherapy
- Key Combination Therapies
- mFOLFOX6, CAPOX, nivolumab, docetaxel, pembrolizumab
- Primary Outcome Measures
- Overall survival, progression-free survival, objective response rate
- Secondary Outcome Measures
- Duration of response, disease control rate, safety and tolerability
- Trial Phases
- Phase 1b, Phase 2, Phase 3
What is Bemarituzumab?
Bemarituzumab (also known as AMG 552) is a new type of cancer drug called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that act like human antibodies in the immune system. They are designed to recognize and attach to specific proteins found on cancer cells.
How Does it Work?
Bemarituzumab specifically targets a protein called fibroblast growth factor receptor 2b (FGFR2b). This protein is found in higher than normal amounts (overexpressed) on the surface of some cancer cells. By attaching to FGFR2b, bemarituzumab may help to slow down or stop the growth of cancer cells.
What Cancers Does it Treat?
Bemarituzumab is being studied for the treatment of several types of cancer, including:
- Gastric (stomach) cancer: This includes cancer of the stomach and the area where the stomach meets the esophagus (called the gastroesophageal junction)
- Squamous cell non-small cell lung cancer (SqNSCLC): A type of lung cancer that starts in the flat cells lining the airways
- Other solid tumors: Bemarituzumab is also being tested in various other types of solid tumors that have high levels of FGFR2b
How is it Given?
Bemarituzumab is given as an intravenous (IV) infusion. This means it is delivered directly into your bloodstream through a vein. The frequency and duration of treatment can vary depending on the specific study and the type of cancer being treated.
Ongoing Research
Several clinical trials are currently underway to study bemarituzumab. These trials are looking at:
- Effectiveness: Researchers are studying how well bemarituzumab works against different types of cancer, especially those with high levels of FGFR2b
- Combination treatments: Many studies are testing bemarituzumab in combination with other cancer treatments, such as chemotherapy or immunotherapy drugs
- Safety and side effects: Researchers are carefully monitoring patients to understand the potential side effects of bemarituzumab
- Personalized treatment: Some studies are using genetic tests to identify patients whose tumors have high levels of FGFR2b, as these patients may be more likely to benefit from bemarituzumab
Potential Side Effects
As with any medical treatment, bemarituzumab may cause side effects. The full range of potential side effects is still being studied. Common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts. Researchers are carefully monitoring patients in clinical trials to identify any specific side effects related to bemarituzumab.
It's important to note that bemarituzumab is still an experimental drug. This means it has not yet been approved by regulatory agencies like the FDA for widespread use. It is only available to patients participating in clinical trials. If you think you might be eligible for a trial involving bemarituzumab, talk to your oncologist about whether this could be an option for you.